TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DORAL

QUAZEPAM
Approved 1985-12-27
1
Indication
--
Phase 3 Trials
40
Years on Market

Details

Status
Discontinued
First Approved
1985-12-27
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: QUAZEPAM

DORAL Approval History

Loading approval history...

What DORAL Treats

1 FDA approvals

Originally approved for its first indication in 1985 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DORAL FDA Label Details

Pro

DORAL Patents & Exclusivity

Latest Patent: Jun 2028

Patents (4 active)

US7608616 Expires Jun 3, 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.